Chemomab Therapeutics Ltd.: insider trades · United States · SEC (Form 4)

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd. (ticker: CMMB) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States (United States). For international equity investors, the company is best understood as a specialty biotech focused on fibro-inflammatory diseases — conditions in which chronic inflammation and fibrosis drive progressive organ damage. Chemomab’s strategy is centered on developing differentiated therapies for indications with substantial unmet medical need, then using clinical data and regulatory milestones to create optionality for partnering, licensing, or eventual commercialization. ([investors.chemomab.com](https://investors.chemomab.com/2026-03-19-Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update?utm_source=openai)) Chemomab’s current corporate identity dates back to its 2021 merger with Anchiano Therapeutics, after which the combined company began trading under the CMMB symbol on the Nasdaq Capital Market. Although the equity trades in the U.S. market, the company’s operational base is in Tel Aviv, Israel, giving it a cross-border profile that is common among development-stage biotechnology issuers seeking access to U.S. capital markets while running research and development outside the United States. ([nasdaq.com](https://www.nasdaq.com/press-release/chemomab-completes-merger-with-anchiano-therapeutics-2021-03-16?utm_source=openai)) The company’s pipeline is highly concentrated around nebokitug, a first-in-class dual-activity monoclonal antibody designed to neutralize soluble CCL24, a protein implicated in fibrotic and inflammatory pathways. Chemomab is advancing nebokitug in primary sclerosing cholangitis (PSC) as its lead clinical opportunity, while also evaluating broader utility in other severe fibro-inflammatory diseases, including systemic sclerosis. According to company disclosures, nebokitug has received important regulatory designations, including FDA Fast Track and orphan-drug status in PSC, as well as orphan-drug recognition for systemic sclerosis in the U.S. and Europe. That gives the asset a clearer development pathway than many early-stage biotech programs, although the company remains pre-commercial and therefore highly dependent on clinical execution. ([investors.chemomab.com](https://investors.chemomab.com/2026-05-14-Chemomab-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update?utm_source=openai)) From a competitive standpoint, Chemomab is a small-cap biotech rather than a diversified pharmaceutical platform. Its value proposition rests on target biology, clinical differentiation, and the potential to address diseases with limited treatment options. The company has reported positive results from five nebokitug clinical trials, and management has said that FDA alignment on a Phase 3 registration study in PSC followed the positive Phase 2 SPRING trial. In its March 19, 2026 update, Chemomab said it completed a successful FDA end-of-Phase 2 meeting and reached alignment on a clear and efficient path toward potential approval in PSC. The company also stated in February 2025 that the World Health Organization’s INN program assigned the nonproprietary name nebokitug to its lead candidate CM-101. ([investors.chemomab.com](https://investors.chemomab.com/2026-03-19-Chemomab-Therapeutics-Announces-Year-End-and-Fourth-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update?utm_source=openai)) Geographically, Chemomab is globally structured: R&D and management are anchored in Israel, while financing, disclosure, and investor access are centered on the U.S. Nasdaq market. Recent corporate updates underscore a company that is moving from proof-of-concept toward later-stage clinical planning. For example, management highlighted the completion of the Phase 2 PSC trial, the ongoing advance of strategic partnership discussions, and a cash runway expected into the end of the first quarter of 2027 as of the company’s March 2026 financial update. For investors, CMMB remains a high-risk/high-upside biotech story driven by regulatory catalysts, clinical readouts, and balance-sheet discipline. ([nasdaq.com](https://www.nasdaq.com/press-release/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results?utm_source=openai))